Ahmed A. Shaaban

Al Mansurah, DK 35516, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

The novel Bruton tyrosine kinase inhibitor branebrutinib abrogates lipopolysaccharide/galactosamine-induced hepatic injury via limiting inflammation and oxidative stress.

The novel Bruton tyrosine kinase inhibitor branebrutinib abrogates lipopolysaccharide/galactosamine-induced hepatic injury via limiting inflammation and oxidative stress.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 20, 2025

Varenicline as a cardioprotective agent against doxorubicin-induced toxicity: A study on apoptotic, TLR4/NF-κB, and inflammasome/caspase-1/IL-1β pathway modulation in a rat model.

Varenicline as a cardioprotective agent against doxorubicin-induced toxicity: A study on apoptotic, TLR4/NF-κB, and inflammasome/caspase-1/IL-1β pathway modulation in a rat model.

Journal: European journal of pharmacology

Published: March 17, 2025

G protein-coupled estrogen receptor selective agonist, G1, improves the molecular and biochemical markers in a cisplatin mouse model of CKD.

G protein-coupled estrogen receptor selective agonist, G1, improves the molecular and biochemical markers in a cisplatin mouse model of CKD.

Journal: Chemico-biological interactions

Published: February 02, 2024

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib.

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib.

Journal: Frontiers in pharmacology

Published: August 22, 2023

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib.

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib.

Journal: Frontiers in pharmacology

Published: April 26, 2023

Emerging roles of tyrosine kinases in hepatic inflammatory diseases and therapeutic opportunities.

Emerging roles of tyrosine kinases in hepatic inflammatory diseases and therapeutic opportunities.

Journal: International immunopharmacology

Published: March 10, 2023

RhoA/ROCK inhibition attenuates endothelin-1-induced glomerulopathy in the rats.

RhoA/ROCK inhibition attenuates endothelin-1-induced glomerulopathy in the rats.

Journal: Life sciences

Published: February 17, 2023

Ameliorative effect of desloratadine against cisplatin-induced renal and testicular toxicity in rats: Attention to TLR4/NLRP3 inflammasome signaling pathway.

Ameliorative effect of desloratadine against cisplatin-induced renal and testicular toxicity in rats: Attention to TLR4/NLRP3 inflammasome signaling pathway.

Journal: Life sciences

Published: November 30, 2022

WITHDRAWN: Vinpocetine and Lactobacillus improve fatty liver in rats via modulating the oxidative stress, inflammation, adiponectin and gut microbiome.

WITHDRAWN: Vinpocetine and Lactobacillus improve fatty liver in rats via modulating the oxidative stress, inflammation, adiponectin and gut microbiome.

Journal: Life sciences

Published: September 30, 2022

Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis.

Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 14, 2022

Digoxin mitigates diethylnitrosamine-induced acute liver injury in mice via limiting production of inflammatory mediators.

Digoxin mitigates diethylnitrosamine-induced acute liver injury in mice via limiting production of inflammatory mediators.

Journal: Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Published: July 27, 2021

The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies.

The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies.

Journal: Toxicology and applied pharmacology

Published: December 21, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026